Panagora Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Panagora Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,881	Closed	-$272K	–	1432
2022 Q3	$272K	Buy	+2,881	New	+$324K	﹤0.01%	1302
2016 Q4	–	Sell	-205	Closed	-$110K	–	2366
2016 Q3	$110K	Buy	+205	New	+$111K	﹤0.01%	1941

Other funds holding ATRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Panagora Asset Management's ATRA Position: Q4 2022 in Review

Panagora Asset Management sold out of Atara Biotherapeutics (ATRA) in Q4 2022, closing a stake of 2,881 shares — an estimated $272K sold.

Panagora Asset Management first reported a position in ATRA in Q3 2016 and held it in 2 quarters. The position peaked at $272K in Q3 2022. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2022.

Panagora Asset Management reported no remaining Atara Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Panagora Asset Management sold 2,881 Atara Biotherapeutics shares in Q4 2022, an estimated $272K.
Panagora Asset Management first reported a position in Atara Biotherapeutics in Q3 2016 and held it in 2 quarters.
Panagora Asset Management's Atara Biotherapeutics position peaked at $272K in Q3 2022.
139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2022.

Based on Panagora Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.